Advanced Safety Sciences for MedicinesContinuing Professional Development and Master’s Courses

Unique CoursesSafeSciMET provides new and unique pan-European education and training in safety sciences for medicines, also covering ethical, regulatoryand societal aspects in all phases of medicines research development. Focus is on holistic, integrative and translational approaches, which werelacking in most programmes to date.

CPD and MastersThe courses can be taken one by one ‘stand alone’, or as subsets of multiple courses, for personal continuing professional development (CPD).Taking a defined number of the twenty SafeSciMET courses and doing a thesis, leads to a Master of Advanced Safety Sciences for Medicines.

AttendeesParticipants of the programme are normally science, life science, medical, biomedical, pharmaceutical and veterinary etc. post-graduates andprofessionals, either currently working in a safety sciences environment and looking for new insight and competence in toxicology and safetysciences topics, or seeking to gain knowledge in safety sciences at a specific point of their career.

OrganisersSafeSciMET, jointly funded by the European Commission and the European pharmaceutical industry (EFPIA), is a public-private partnershipnetwork, there to solve a shortfall in Europe identified by EUFEPS and other representing the scientific community. It was established in 2010and is made up of top academic institutions for medicines safety education, training and research, together with pharmaceutical companies.

Remaining 2nd Cycle SafeSciMET Courses

Information and RegistrationThe SafeSciMET Student Office at www.safescimet.eu or info@safescimet.eu or by telephone +46 701 679130

http://dx.doi.org/10.1016/S0928-0987(13)00251-0

3.2: Cellular Toxicology/Predictive Toxicology van de Water/von Keutz Leiden 24.6.2013 – 28.6.2013

3.3: Organ/Systems Toxicology Dietrich/Karlsson Constance 30.9.2013 – 4.10.2013

3.4: Reproductive Toxicology Stahlmann/Bouisset-Leonard Berlin 21.10.2013 – 25.10.2013

3.5: Mutagenesis and Carcinogenesis Grasl-Kraupp/Martus Vienna 18.11.2013 – 22.11.2013

3.6: Safety Pharmacology Park/Goldring/Williams Liverpool 25.11.2013 – 29.11.2013

4.1: Non-Clinical Safety Assessment: Strategies.Ethics and Protocols

Schmerold/Foth Vienna 9.12.2013 – 13.12.2013

4.2: Biomolecular Analysis: From MethodDevelopment to Clinic

Niessen/Herling Amsterdam 13.1.2014 – 17.1.2014

4.3: Predictive Cell Culture Systems Foth/Mueller Halle 3.2.2014 – 7.2.2014

4.4: Toxicogenomics and Systems Toxicology Meerman/Hewitt Leiden 10.3.2014 – 14.3.2014

4.5: Pathology Interpretation in Drug Development Price Surrey 5.5.2014 – 9.5.2014

4.6: In silico ADME and Predictive Toxicology Steen Jørgensen/Amberg Copenhagen 19.5.2014 – 23.5.2014

5.1: Clinical Safety: Pre-Approval Dietrich/Doessegger Basel 2.6.2014 – 6.6.2014

5.2: Clinical Safety: Post-Approval Dietrich/Caplain Paris 23.6.2014 – 27.6.2014

5.3: Stratification: Pharmacogenetics and Drug Safety Ingelman-Sundberg/McHale Stockholm 25.8.2014 – 29.8.2014

European Journal of Pharmaceutical Sciences 49 (2013) I

Contents lists available at SciVerse ScienceDirect

European Journal of Pharmaceutical Sciences

journal homepage: www.elsevier .com/ locate/e jps